Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 6/2016

01-12-2016 | Myelodysplastic Syndromes (D Steensma, Section Editor)

Palliative and End-of-Life Care in Myelodysplastic Syndromes

Authors: Myles Nickolich, Areej El-Jawahri, Thomas W. LeBlanc

Published in: Current Hematologic Malignancy Reports | Issue 6/2016

Login to get access

Abstract

A growing literature demonstrates that MDS is associated with significant impairments in overall quality of life. Given the poor prognosis for many patients with MDS, and the considerable morbidities associated with this disease, there is a critical need to address palliative and end-of-life care needs in this population. However, palliative and end-of-life care issues are under-represented in the MDS literature. In this article, we highlight a growing body of literature that demonstrates unmet palliative and end-of-life care needs in hematologic malignancies, including MDS, and highlight opportunities for further research and quality improvement initiatives to address unmet needs in MDS care.
Literature
1.
Vardiman JW et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMed
2.
Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):287–94.CrossRefPubMed
3.
4.
5.
Malcovati L et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–10.CrossRefPubMed
6.
List A et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.CrossRefPubMed
7.
8.
Fenaux P et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.CrossRefPubMedPubMedCentral
9.
Luger SM et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47(2):203–11.CrossRefPubMed
10.
El-Jawahri A et al. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016;51(8):1121–6.CrossRefPubMed
11.••
LeBlanc TW, El-Jawahri A. When and why should patients with hematologic malignancies see a palliative care specialist? Hematology Am Soc Hematol Educ Program. 2015;2015:471–8. This manuscript describes the modern specialty of palliative care, and provides recommendations about when and how to incorporate specialist palliative care into the management of patients with hematologic malignancies.PubMed
12.
LeBlanc TW. Palliative care and hematologic malignancies: old dog, new tricks? J Oncol Pract. 2014;10(6):e404-7.
13.
LeBlanc TW. Addressing end-of-life quality gaps in hematologic cancers: the importance of early concurrent palliative care. JAMA Intern Med. 2016;176(2):265–6.CrossRefPubMed
14.
15.
Odejide OO, et al. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014;10(6):e396-403.
16.
Hui D et al. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015;26(7):1440–6.PubMedPubMedCentral
17.
LeBlanc TW, et al. Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. J Oncol Pract. 2015;11(2):e230-8.
18.
Heptinstall K, I. Myelodysplastic Syndromes Foundation. Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc. Oncology (Williston Park). 2008;22(2 Suppl Nurse Ed):13–8. discussion 19.
19.
Steensma DP et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008;32(5):691–8.CrossRefPubMed
20.
Efficace F et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015;168(3):361–70.CrossRefPubMed
21.
Oliva EN et al. Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res. 2012;2(2):136–47.PubMedPubMedCentral
22.
Abel GA et al. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014;123(3):451–2.CrossRefPubMed
23.
Lucioni C et al. Costs and quality of life in patients with myelodysplastic syndromes. Am J Blood Res. 2013;3(3):246–59.PubMedPubMedCentral
24.
Caocci G et al. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue. Leuk Res. 2007;31(2):249–52.CrossRefPubMed
25.
Deschler B et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208–16.CrossRefPubMedPubMedCentral
26.
Efficace F et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol. 2015;16(15):1506–14.CrossRefPubMed
27.
Thomas ML. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res. 1998;22 Suppl 1:S41–7.CrossRefPubMed
28.
Bakitas M et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA. 2009;302(7):741–9.CrossRefPubMedPubMedCentral
29.
Bakitas MA et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33(13):1438–45.CrossRefPubMedPubMedCentral
30.
Grudzen CR, Richardson LD, Johnson PN, Hu M, Wang B, Ortiz JM, et al. Emergency Department-Initiated Palliative Care in Advanced Cancer: a randomized clinical trial. JAMA Oncol. 2016. doi:10.​1001/​jamaoncol.​2015.​5252.
31.
Temel JS et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.CrossRefPubMed
32.
Zimmermann C et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet. 2014;383(9930):1721–30.CrossRefPubMed
33.
Deeg HJ. Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients. Bone Marrow Transplant. 2015;50(9):1145–9.CrossRefPubMed
34.
Thomas ML, Crisp N, Campbell K. The importance of quality of life for patients living with myelodysplastic syndromes. Clin J Oncol Nurs. 2012;16(Suppl):47–57.CrossRefPubMed
35.
Ansell P et al. What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records. Palliat Med. 2007;21(6):487–92.CrossRefPubMed
36.
Salacz ME, Lankiewicz MW, Weissman DE. Management of thrombocytopenia in bone marrow failure: a review. J Palliat Med. 2007;10(1):236–44.CrossRefPubMed
37.••
Fletcher SA et al. Intensity of end-of-life care for patients with myelodysplastic syndromes: findings from a large national database. Cancer. 2016;122(8):1209–15. This manuscript conclusively demonstrates the poor end-of-life care MDS patients receive in the U.S. CrossRefPubMed
38.
Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908–15.CrossRefPubMed
39.
Kasner MT, Luger SM. Update on the therapy for myelodysplastic syndrome. Am J Hematol. 2009;84(3):177–86.CrossRefPubMed
40.
Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91(1):76–89.CrossRefPubMed
41.
42.
Howell DA et al. Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. BMC Palliat Care. 2010;9:9.CrossRefPubMedPubMedCentral
43.
Howell DA et al. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011;25(6):630–41.CrossRefPubMed
44.
Fadul N et al. Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med. 2007;10(5):1146–52.CrossRefPubMed
45.
LeBlanc TW, Abernethy AP, Casarett DJ. What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network. J Pain Symptom Manage. 2015;49(3):505–12.CrossRefPubMed
46.
Odejide OO, Cronin AM, Earle CC, LaCasce AS, Abel GA. Hospice use among patients with lymphoma: impact of disease aggressiveness and curability. J Natl Cancer Inst. 2015;108(1). doi:10.​1093/​jnci/​djv280.
47.
Cheng WW et al. Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med. 2005;8(5):1025–32.CrossRefPubMed
48.
Howell DA, Wang HI, Roman E, Smith AG, Patmore R, Johnson MJ, et al. Preferred and actual place of death in haematological malignancy. BMJ Support Palliat Care. 2015. doi:10.​1136/​bmjspcare-2014-000793.
49.
Niscola P et al. Caring for terminal patients in haematology: the urgent need of a new research agenda. Support Care Cancer. 2015;23(1):5–7.CrossRefPubMed
50.
LeBlanc TW. In the sandbox: palliative care and hematologic malignancies. J Commun Supp Oncol. 2014;12(2):44–5.CrossRef
51.
Odejide OO, Cronin AM, Condron NB, Fletcher SA, Earle CC, Tulsky JA, et al. Barriers to quality end-of-life care for patients with blood cancers. J Clin Oncol. 2016;34(26):3126–32.
52.
Hui D et al. Attitudes and beliefs toward supportive and palliative care referral among hematologic and solid tumor oncology specialists. Oncologist. 2015;20(11):1326–32.CrossRefPubMedPubMedCentral
53.•
LeBlanc TW, et al. Discussing the evidence for upstream palliative care in improving outcomes in advanced cancer. Am Soc Clin Oncol Educ Book. 2016;35:e534-8. This manuscript summarizes the major randomized trials of early palliative care in oncology. The benefits of concurrent palliative care alongside active cancer therapy are truly remarkable, and should be tested further in hematology.
Metadata
Title
Palliative and End-of-Life Care in Myelodysplastic Syndromes
Authors
Myles Nickolich
Areej El-Jawahri
Thomas W. LeBlanc
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 6/2016
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-016-0352-z

Other articles of this Issue 6/2016

Current Hematologic Malignancy Reports 6/2016 Go to the issue

Acute Myeloid Leukemias (H Erba, Section Editor)

Definition of Unfit for Standard Acute Myeloid Leukemia Therapy

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

T-cell Lymphoma Epidemiology: the Known and Unknown

Myelodysplastic Syndromes (D Steensma, Section Editor)

Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts

Myelodysplastic Syndromes (D Steensma, Section Editor)

An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM

Acute Myeloid Leukemias (H Erba, Section Editor)

Antibody-Based Treatment of Acute Myeloid Leukemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits